Drug Information

General Information
Drug ID
DR00116
Drug Name
Lamivudine
Synonyms
(+/-)-(Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (+/-)-3TC; (+/-)-BCH-189; (+/-)-SddC; (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine; (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-2'-Deoxy-3'-thiacytidine; (-)-BCH 189; (-)-BCH-189; (-)-NGPB-21; (-)-SddC; (-)-beta-L-2',3'-Dideoxy-3'-thiacytidine; (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 2',3' Dideoxy 3' thiacytidine; 2',3'-Dideoxy-3'-thiacytidine; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-)-(Cis); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Galanthus Nivalis Agglutinin (GNA); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Hippeastrum hybrid agglutinin(HHA); 3'-Thia-2',3'-dideoxycytidine; 3TC; 3TC & GNA; 3TC & SST; 3TC (AIDS INITIATIVE) (AIDS INITIATIVE); 3TC and NV-01; 3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine; 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; BCH 189; BCH-189; BCH-790; BCH189; Beta-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To; Beta-L-2',3'-Dideoxy-3'-thiacytidine; Beta-L-3'-Thia-2',3'-dideoxycytidine; DRG-0126; DTHC; Epivir; Epivir (TN); Epivir(TM); Epivir-HBV; Epivir-HBV (TN); GG-714; GR-109714X; GR109714X; HHA & 3TC; HHA & Lamivudine; Hepitec; Heptivir; Heptodin; Heptovir; Heptovir (TN); LMV; Lamivir; Lamivudine & GNA; Lamivudine (JAN/USP/INN); Lamivudine [USAN:BAN:INN]; Lamivudine [USAN:INN:BAN]; Lamivudine, (2S-cis)-Isomer; Zeffix; Zeffix (TN); Zefix
Drug Type
Small molecular drug
Indication Chronic hepatitis B infection [ICD11: 1E51.0] Approved [1]
Human immunodeficiency virus infection [ICD11: 1C62.Z] Approved [1]
Therapeutic Class
Anti-HIV Agents
Structure
3D MOL 2D MOL
Formula
C8H11N3O3S
Canonical SMILES
C1C(OC(S1)CO)N2C=CC(=NC2=O)N
InChI
InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1
InChIKey
JTEGQNOMFQHVDC-NKWVEPMBSA-N
CAS Number
CAS 134678-17-4
Pharmaceutical Properties Molecular Weight 229.26 Topological Polar Surface Area 113
Heavy Atom Count 15 Rotatable Bond Count 2
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 4
XLogP
-0.9
PubChem CID
60825
PubChem SID
103195019 , 103977094 , 104170203 , 104253324 , 104321740 , 11528367 , 117588081 , 118048664 , 12014700 , 12016245 , 121362453 , 124658974 , 124757443 , 124892101 , 125164247 , 126584422 , 126592947 , 126625491 , 126656696 , 126665392 , 127310181 , 127310182 , 14798125 , 15121620 , 24277302 , 26719826 , 29215254 , 3727051 , 3727058 , 43118163 , 46386600 , 46507855 , 49681736 , 50140269 , 57314135 , 596236 , 601313 , 643736 , 7847419 , 7979719 , 81093205 , 811475 , 8187080 , 85279382 , 87560180 , 92308311 , 92712464 , 92729822 , 9277 , 93166191
ChEBI ID
ChEBI:63577
TTD Drug ID
D07TQV
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
OCT-1 Transporter Info Organic cation transporter 1 Substrate [3]
OCT-2 Transporter Info Organic cation transporter 2 Substrate [4]
Drug-Transporter Activity Data
Drug-Transporter Activity Data OCT-2 Transporter Info Km = 46.3 microM Oocytes-OCT2 [4]
References
1 Salicylic acid was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. Br J Clin Pharmacol. 2007 Nov;64(5):645-54.
3 Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos. 2008 Aug;36(8):1616-23.
4 Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake. Biopharm Drug Dispos. 2012 Apr;33(3):170-8.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.